Status: Phase 3
Entry Type: Antibody
Molecule Category: UNKNOWN

Indications

Mesh Heading Maximum Phase Reference
Arthritis; Arthritis, Rheumatoid Phase 3 ClinicalTrials
Arthritis; Arthritis, Rheumatoid Phase 2 ClinicalTrials
Arthritis; Arthritis, Rheumatoid Phase 2 ClinicalTrials
Arthritis; Arthritis, Rheumatoid Phase 2 ClinicalTrials
Autoimmune Diseases; Connective Tissue Diseases; Lupus Erythematosus, Systemic Phase 3 ClinicalTrials
Autoimmune Diseases; Connective Tissue Diseases; Lupus Erythematosus, Systemic Phase 3 ClinicalTrials
Arthritis; Arthritis, Rheumatoid Phase 3 ClinicalTrials
Arthritis; Arthritis, Rheumatoid Phase 2 ClinicalTrials
Arthritis; Arthritis, Rheumatoid Phase 1 ClinicalTrials
Arthritis; Arthritis, Rheumatoid Phase 3 ClinicalTrials
Multiple Myeloma; Neoplasms, Plasma Cell Phase 1 ClinicalTrials
Kidney Diseases; Kidney Failure, Chronic; Renal Insufficiency Phase 2 ClinicalTrials
Arthritis; Arthritis, Rheumatoid Phase 2 ClinicalTrials
Autoimmune Diseases; Connective Tissue Diseases; Lupus Erythematosus, Systemic Phase 3 ClinicalTrials
Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Sclerosis Phase 2 ClinicalTrials
Arthritis; Arthritis, Rheumatoid Phase 3 ClinicalTrials
CONTENTS